期刊
FUTURE ONCOLOGY
卷 13, 期 24, 页码 2183-2193出版社
FUTURE MEDICINE LTD
DOI: 10.2217/fon-2017-0245
关键词
circulating tumor DNA; GIST; KIT; PDGFR alpha; quadruple WT GIST
类别
资金
- ArQule
- Daiichi Sankyo
- Merck Sharp Dohme
- Novartis
Gastrointestinal stromal tumors (GISTs) are the most common GI tract mesenchymal tumors. GIST patients are optimally managed by a precision medicine approach. Herein, we discuss the latest advances in precision medicine and ongoing clinical trials relevant to GIST. Circulating tumor DNA for detection of mutational changes could replace tissue biopsies and radiographic imaging once validated. Most GISTs are KIT/PDGFR alpha mutated, and despite the good clinical response to imatinib, treatment is generally not curative, more often due to secondary mutations. New mechanisms to bypass this resistance by inhibiting KIT downstream pathways and by targeting multiple KIT or PDGFR alpha mutations are being investigated. Immunotherapy for GIST patients is in its infancy. These approaches may lead to more effective, less toxic therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据